Efficacy and Safety of Bortezomib in Multiple Myeloma Patients with Hepatitis B： A Multicenter Retrospective Study
Efficacy and Safety of Bortezomib in Multiple Myeloma Patients with Hepatitis B： A Multicenter Retrospective Study作者机构：Department of Hematology Peking University People's Hospital and Peking University Institute of Hematology Beijing 100044 China Department of Hematology Beijing Chao-Yang Hospital Beijing 100020 China Southwest Oncology Group International Myeloma Foundation and Cedars Sinai Comprehensive Cancer Center Los Angeles CA 90048 USA
出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)
年 卷 期：2016年第129卷第3期
页 面：274-278页
核心收录：
学科分类：0710[理学-生物学] 1002[医学-临床医学] 07[理学] 071009[理学-细胞生物学] 071007[理学-遗传学]
主 题：Bortezomib Hepatitis B Lamivudine Myeloma Thalidomide
摘 要：Background： The efficacy and safety evidence of bortezomib in multiple myeloma （MM） patients with hepatitis B is vacant.This study aimed to investigate the efficacy and safety of bortezomib in MM patients with hepatitis B in China.Methods： From 2006 to 2011, 739 newly diagnosed MM patients were screened for serum hepatitis B virus （HBV） biomarkers.HBV-infected patients were followed for HBV reactivation by monitoring of serum alanine transaminase （ALT） and HBV DNA load.The pattern of HBV reactivation in relation to bortezomib was evaluated.Seven hundred thirty-nine MM patients were included in this study.Results： The prevalence of MM patients infected with HBV was 3.4% （n =25）, of which 17 cases were treated with bortezomib.Bortezomib had no significant influence on liver function （ALT before and after treatment： 36.69 ＆#177; 8.90 U/L vs.11.31 ＆#177; 2.74 U/L, P =0.19） and HBV DNA of MM patients with HBV （detectable HBV DNA percentage： 5.9% vs.11.8%, P =0.12）.Conclusions： Bortezomib can be used safely and effectively in MM patients with hepatitis B.HBV prophylaxis and surveillance are recommended during the MM treatment.
维普期刊数据库
同方期刊数据库